Hannah Joseph (544687)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Hospital industry provides essential healthcare demand, offering a relatively stable business backdrop.
• Latest quarter shows positive operating traction: sales of ₹43 Cr and net profit of ₹5 Cr.
• ROCE of 16.97% indicates decent capital efficiency at the operating level.
• Small market cap of ₹137 Cr leaves room for niche growth if management executes well.

Concerns

• Piotroski F-Score of 3/9 is weak, suggesting poor fundamental health and financial discipline.
• Both sales growth and profit growth are 0.00%, with no dividend, so there is no current return or expansion.
• Critical data gaps—P/B, ROE, debt/equity, and promoter holding—make the balance sheet and governance unverifiable.
• At a P/E of 18.95 with zero growth, the valuation offers no margin of safety.

AI Analysis

At ₹60.18, Hannah Joseph wears a market cap of just ₹137 Cr. In Graham's language, a small hospital can be a good business, but a good investment requires numbers. The latest quarter shows sales of ₹43 Cr and net profit of ₹5 Cr. Annualised, that profit is around ₹20 Cr, which would make the P/E far cheaper than the stated 18.95—but the stated P/E and zero sales/profit growth tell me the trailing twelve months are less impressive. With zero growth, paying 18.95 times earnings is not a bargain. ROCE of 16.97% is respectable; it suggests the company generates decent returns on capital employed. But without book value, ROE, or debt/equity, I cannot judge leverage or true shareholder returns. The Piotroski F-score of 3 out of 9 is a red flag—it signals weak fundamentals across profitability, leverage, and efficiency. There is no dividend, so the investor relies entirely on price appreciation. In a hospital, quality comes from reputation, doctors, and execution; none of that is visible here. The data is insufficient. Buffett would say: it is far better to lose an opportunity than to invest in ignorance. This is not a fast grower; it is a slow grower at best, with warning lights. I would need much more disclosure—especially debt, promoter holding, and a history of cash flows—before putting any money to work. For now, I stay with the simpler calculation: no growth, no dividend, low F-score, and insufficient information. That is not a margin of safety.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer